AstraZeneca has lodged its appeal over losing the patent for hypertension treatment Toprol XL (metoprolol succinate). In January US court ruled that two patents for the extended release tablet were invalid and unenforceable finding in favour of the defendants KV Pharmaceutical, Andrx Corp and Novartis’s Eon Labs.


Fatal error: Call to undefined function is_syndicated() in /home/meddisco/public_html/wp-content/themes/executive-pro/single.php on line 32